Related Experiment Videos
Tumor cyclooxygenase 2-dependent suppression of dendritic cell function
Sherven Sharma1, Marina Stolina, Seok-Chul Yang
1University of California Los Angeles School of Medicine-Wadsworth Pulmonary Immunology Laboratory, VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA.
Summary
Tumor cyclooxygenase-2 (COX-2) impairs dendritic cell (DC) function, hindering antitumor immunity. Inhibiting COX-2 restores DC activity, promoting effective anti-cancer immune responses.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Dendritic cells (DCs) are crucial for initiating anti-tumor immune responses by presenting tumor antigens.
- The tumor microenvironment can suppress DC function, limiting their effectiveness.
- Cyclooxygenase-2 (COX-2) is implicated in tumor progression and immune modulation.
Purpose of the Study:
- To investigate the impact of tumor COX-2 expression on dendritic cell function.
- To determine if inhibiting COX-2 can restore DC activity and anti-tumor immunity.
Main Methods:
- Bone marrow-derived DCs were cultured in tumor supernatant (TSN) with or without COX-2 inhibition.
- DC phenotype, antigen processing/presentation, alloreactivity, and cytokine secretion (IL-10, IL-12) were assessed in vitro.
- The ability of pulsed DCs to generate anti-tumor immune responses was evaluated in a murine lung cancer model.
Main Results:
- DCs cultured in TSN exhibited impaired antigen presentation, reduced alloreactivity, and decreased IL-12 secretion.
- TSN-cultured DCs showed reduced expression of key surface markers (e.g., CD11c, MHC class II, CD80, CD86).
- Inhibition of tumor COX-2 restored DC function and led to effective anti-tumor immune responses in vivo.
Conclusions:
- Tumor-derived COX-2 actively suppresses dendritic cell function within the tumor microenvironment.
- Inhibiting tumor COX-2 is a viable strategy to enhance DC-mediated anti-tumor immunity.
- Targeting COX-2 may overcome immune suppression and improve cancer immunotherapy outcomes.